根據(jù)4月15日Cancer Research期刊中的最新報導指出，美國費城威斯達研究所（Wistar Institute）的研究者發(fā)展出一種新的抗原復制技術(shù),，成功識別出一個新的腫瘤抗原核糖體蛋白L8（ribosomal protein L8,；RPL8）。
近年來,，學者專家們漸漸著手開發(fā)腫瘤疫苗作為治療癌癥的方式,。不同于一般「疫苗」的概念，腫瘤疫苗并非用來「預防」癌癥,，而是利用增強免疫反應,，來殲滅已經(jīng)存在的腫瘤。
與傳統(tǒng)治療癌癥方法相比,，腫瘤疫苗具有較低的毒性與較高的效能,。然而，至今僅針對活化T輔助細胞（T helper cell,，THL）的疫苗有較佳的成效,。「先前類似的黑色素瘤疫苗多為活化殺手T細胞（cytotoxic T-lymphocytes,，CTL）,，」威斯達研究所分生與免疫學教授Dorothee Herlyn博士表示：「我們的方法所分離到的RPL8疫苗則是對于活化CTL與THL兩者兼具,。」
核糖體蛋白L8是常見于各個細胞中,、合成蛋白質(zhì)必要的酵素,，唯在黑色素瘤、乳癌與腦癌中有高度表現(xiàn),。Herlyn博士指出,，這項新的方式是利用噬菌體來攜帶抗原感染B細胞后，藉由B細胞的抗原呈現(xiàn)機制,，能夠更直接而長效的活化免疫系統(tǒng),。「我們也會朝向乳癌和腦癌疫苗方向努力開發(fā),，以期早日能夠有效治療這些癌癥,。」她說,。
(資料來源 : bio)
原始出處:
Cancer Research 67, 3555-3559, April 15, 2007. doi: 10.1158/0008-5472.CAN-06-2763
Priority Reports
Shared MHC Class II–Dependent Melanoma Ribosomal Protein L8 Identified by Phage Display
Rolf K. Swoboda1, Rajasekharan Somasundaram1, Laura Caputo1, Elizabeth M. Ochoa1, Phyllis A. Gimotty2, Francesco M. Marincola7, Patricia Van Belle4, Stephen Barth4, David Elder3,4, DuPont Guerry3,5, Brian Czerniecki3,6, Lynn Schuchter3,5, Robert H. Vonderheide3 and Dorothee Herlyn1
1 The Wistar Institute; 2 Center for Epidemiology and Biostatistics and 3 Abramson Cancer Center, University of Pennsylvania; Departments of 4 Pathology, 5 Medicine, and 6 Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and 7 Department of Transfusion Medicine Clinical Center, NIH, Bethesda, Maryland
Requests for reprints: Dorothee Herlyn, Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104. Phone: 215-898-3962; Fax: 215-898-0980; E-mail: [email protected] .
Antigens recognized by T helper (Th) cells in the context of MHC class II molecules have vaccine potential against cancer and infectious agents. We have described previously a melanoma patient's HLA-DR7–restricted Th cell clone recognizing an antigen, which is shared among melanoma and glioma cells derived from various patients. Here, this antigen was cloned using a novel antigen phage display approach. The antigen was identified as the ribosomal protein L8 (RPL8). A peptide of RPL8 significantly stimulated proliferation and/or cytokine expression of the Th cell clone and lymphocytes in four of nine HLA-DR7+ melanoma patients but not in healthy volunteers. The RPL8 antigen may represent a relevant vaccine target for patients with melanoma, glioma, and breast carcinoma whose tumors express this protein. [Cancer Res 2007;67(8):3555–9]
